News|Articles|August 1, 2026

6 Allergy Headlines You Missed in July 2026

Fact checked by: Tim Smith

FDA expands Ryaltris to younger children with seasonal allergic rhinitis, Palforzia discontinues, and HAE's oral pipeline widens with deucrictibant and sebetralstat.

July brought major shifts across food allergy, hereditary angioedema (HAE), and allergic rhinitis care. Palforzia's discontinuation closed the chapter on the first FDA-approved peanut oral immunotherapy (OIT), while new omalizumab (Xolair) data reinforced a biologic alternative for multifood allergy.